一家名为 Mass Balance 的英国新创公司最近向太空发射了一个自主进行化学实验的微型装置，以测试其在微重力环境下的运行与数据采集能力。该实验旨在研究在地球上因重力干扰而难以观测的致病蛋白质，借此为长寿研究开辟新领域。

在地球上，与阿兹海默症及癌症等老年疾病相关的无序蛋白质会不断改变形状，这导致 AlphaFold 等生命科学模型因缺乏训练数据而无法预测其行为。微重力环境能消除对流和沉淀等物理效应，使科学家得以更精确地分析这些蛋白质，并计划利用这些太空数据来训练 AI 模型以开发新药。

与 BioOrbit 和 Varda Space 等其他试图将太空实验室完整带回地球的生技公司不同，Mass Balance 的设备不需要回收，从而避开了重返大气层的高温与压力挑战。此次任务的主要目标是验证其系统，对一种工业生物催化剂在太空中的化学反应进行监测。

A British startup named Mass Balance recently launched a miniature device for autonomous chemical experiments into space to test its operational and data capture capabilities under microgravity. The experiment aims to study disease-causing proteins that are difficult to observe on Earth due to gravitational interference, opening a new frontier in longevity research.

On Earth, disordered proteins linked to age-related illnesses like Alzheimer's and cancer constantly change shape, leaving life sciences models like AlphaFold without training data to predict their behavior. Microgravity eliminates physical effects like convection and sedimentation, allowing scientists to analyze these proteins precisely and train AI models with space-derived data for drug development.

Unlike other biotech startups such as BioOrbit and Varda Space, which aim to bring their space laboratories back to Earth intact, Mass Balance does not require recovery, avoiding the challenges of extreme heat and stress during atmospheric re-entry. The primary goal of this mission is to validate the system by monitoring the chemical reaction of an industrial biocatalyst in space.